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To determine differences in the ability of Mycobacterium 
tuberculosis strains to withstand antituberculosis drug 
treatment, we compared the activity of antituberculosis 
drugs against susceptible Beijing and East-African/Indian 
genotype M. tuberculosis strains. Beijing genotype strains 
showed high rates of mutation within a wide range of 
drug concentrations, possibly explaining this genotype’s 
association with multidrug-resistant tuberculosis.
The emergence of Mycobacterium tuberculosis resistance to antituberculosis (anti-TB) drugs is a 
major public health challenge that is threatening World 
Health Organization targets set for the elimination of 
TB (1). Approximately 500,000 cases of multidrug-
resistant TB (MDR TB) are diagnosed annually, but the 
true magnitude of the MDR TB problem is not known 
because adequate laboratory tools are lacking. Multiple 
factors contribute to low cure rates, treatment failures, 
and relapses: poor-quality guidance regarding treatment, 
HIV co-infection, transmission of resistant forms of TB, 
underdeveloped laboratory services, and unavailability of 
alternative drug treatments. However, the evolution of M. 
tuberculosis is an additional factor that presumably fuels 
the worldwide problem of emerging resistance. The Beijing 
genotype is signifi cantly associated with drug resistance 
(2,3), especially in geographic areas where prevalence of 
resistance to anti-TB drugs is high, and it is associated with 
recent TB transmission (2–6). There are also indications 
that the population structure of M. tuberculosis in areas 
with a high prevalence of anti-TB drug resistance is 
changing rapidly toward an increase in Beijing genotype 
strains (2,6–8).
The World Health Organization target rates for 
detecting and curing TB in Vietnam have been met; 
however, the rate of TB infection is not decreasing as 
expected (4,5). Earlier in this country, the Beijing genotype 
was strongly correlated with MDR TB and treatment 
failures (9). Extensive molecular epidemiologic studies 
showed that the Beijing and East-African/Indian (EAI) 
genotypes are predominating in Vietnam; each lineage 
causes ≈40% of the TB cases. According to the single-
nucleotide polymorphism typing described by Hershberg 
et al. (10), the Beijing genotype is a representative of 
the modern lineage, and the EAI genotype is believed to 
represent an evolutionary lineage more closely related to 
the common ancestor of the M. tuberculosis complex.
We compared the in vitro activity of anti-TB drugs 
against susceptible Beijing and EAI M. tuberculosis 
isolates from Vietnam and determined the in vitro mutation 
frequency of these strains during drug exposure. We also 
determined time-kill kinetics of anti-TB drugs and assessed 
the emergence of resistant mutants and the concentration 
range within which resistant mutants and no susceptible 
mycobacteria were selected. The concentration at which 
resistant mutants did not emerge (the mutant prevention 
concentration) was also ascertained. By using this 
approach, we established an in vitro model for determining 
differences in the ability of M. tuberculosis strains to resist 
anti-TB drug treatment.
The Study
Results of a liquid culturing system (BD BACTEC 
MGIT 960 System; BD Diagnostics, Sparks, MD, US) 
(for details, see the online Technical Appendix, wwwnc.
cdc.gov/EID/pdfs/11-0912-Techapp.pdf) showed that all 
5 Beijing and 5 EAI genotype strains were susceptible to 
isoniazid (INH), rifampin (RIF), moxifl oxacin (MXF), 
and amikacin (AMK). MICs were determined by using the 
agar proportion method (11), which showed that ranges 
were small for the Beijing and EAI genotype strains: INH, 
0.062–0.125 mg/L; RIF, 0.125–1 mg/L; MXF, 0.125–0.5 
mg/L; and AMK, 0.5–2 mg/L. Duplicate values showed 
only minor differences.
We determined the mutation frequencies of the Beijing 
and EAI genotype strains by using previously defi ned 
critical drug concentrations of 1 mg/L for INH, RIF, and 
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MXF and 5 mg/L for AMK (11,12) (for details, see the 
online Technical Appendix). The mutation frequencies of 
the Beijing and EAI genotype strains were similar for INH, 
MXF, and AMK, but they were signifi cantly different for 
RIF (1.6 × 10−5 to 5.4 × 10−3 for Beijing strains vs. 6.3 × 10−8 
to 3.8 × 10−4 for EAI strains; p = 0.003, unpaired Mann-
Whitney test) (Table 1; Figure 1). Because rifamycin drugs 
are widely used to treat TB, the difference in the mutation 
frequencies of Beijing and EAI genotype strains for RIF is 
a major fi nding.
For Beijing genotype strains, the increase in mutation 
frequency during exposure to RIF could be due to described 
missense mutations in the mut genes (13). Such mutations 
in the mut genes can change the DNA repair mechanism; as 
a consequence, the frequency of resistant mutant formation 
might increase. However, a direct correlation between the 
occurrence of particular mutations in mut genes and altered 
mutation frequency has not been proven. Furthermore, 
Werngren and Hoffner (14) found an equal mutation 
frequency for Beijing (3.6 × 10−8) and non-Beijing (4.4 × 
10−8) genotypes. A possible explanation for the discrepancy 
in fi ndings might be the concentration of RIF used in the 
subculture plates. In our study, the critical concentration 
of 1 mg/L RIF was used (11), whereas Werngren and 
Hoffner used a concentration of 2 mg/L RIF. In addition, 
Werngren and Hoffner compared the Beijing and non-
Beijing genotypes of several genotype families, whereas 
we compared Beijing and EAI genotype strains that were 
selected from the same tuberculosis-endemic area and 
during the same period.
We determined the time-kill kinetics of RIF toward 2 
strains with signifi cantly different mutation frequencies: 
Beijing-1585 (3.7 × 10−3 [3.0 × 10−3 and 4.3 × 10−3, 
duplicates]) and EAI-1627 (3.5 × 10−6 [2.8 × 10−6 and 4.1 × 
10−6, duplicates]). Cultures with low and high densities of 
Beijing-1585 and EAI-1627 were investigated as described 
(15). RIF showed strong time- and concentration-dependent 
activity toward low-density cultures of the 2 strains (Figure 
2). Low concentrations of RIF were needed to achieve >99% 
mycobacterial killing; differences between Beijing-1585 
and EAI-1627 were minor (Table 2). However, to 
achieve 100% killing, especially for Beijing-1585, RIF 
concentrations had to be increased substantially (Table 2). 
Compared with the low-density culture for Beijing-1585, 
a substantial increase in RIF concentrations was needed to 
achieve 100% killing of the high-density culture (Table 2). 
This fi nding may be relevant in the clinical context because 
high-density mycobacteria populations are expected to 
exist in infected tissues of TB patients.
RIF-resistant mutants did not emerge in low-density 
cultures of Beijing-1585 and EAI-1627. However, RIF-
resistant mutants were selected at relatively high numbers 
from high-density Beijing-1585 cultures compared with 
high-density EAI-1627 cultures. In Beijing-1585 cultures, 
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Table 1. Mutation frequency of Mycobacterium tuberculosis genotype strains originating from Vietnam, by antituberculosis drug 
Genotype 
Frequency of mutation among strains* 
Isoniazid Rifampin Moxifloxacin Amikacin 
Beijing     
 1585 5.7 × 106, 6.2 × 106 3.0 × 103, 4.3 × 103 4.3 × 108, 6.1 × 108 2.3 × 108, 3.2 × 108
 1607 8.6 × 106, 1.4 × 105 1.5 × 103, 5.4 × 103 6.9 × 108, 2.4 × 107 8.6 × 108, 3.0 × 107
 2115 7.3 × 106, 1.1 × 105 1.0 × 103, 9.2 × 105 1.0 × 108, 4.3 × 108 1.4 × 108, 2.8 × 108
 2121 6.8 × 105, 2.9 × 104 2.9 × 105, 1.9 × 104 1.1 × 107, 1.6 × 107 9.3 × 108, 1.1 × 107
 2145 9.1 × 104, 5.0 × 104 1.6 × 105, 5.5 × 105 7.9 × 108, 1.0 × 107 7.6 × 107, 1.1 × 106
East-African/Indian     
 1627 3.7 × 106, 6.5 × 106 4.1 × 106, 2.8 × 106 9.3 × 109, 1.5 × 107 5.6 × 108, 4.5 × 109
 1606 8.7 × 106, 1.6 × 104 3.8 × 104, 2.7 × 105 3.2 × 108, 1.0 × 107 7.5 × 109, 1.5 × 109
 1592 1.8 × 105, 2.6 × 105 3.0 × 104, 2.4 × 105 9.9 × 108, 4.5 × 108 9.4 × 108, 1.5 × 109
 1596 3.9 × 105, 2.8 × 105 1.4 × 105, 3.9 × 106 1.7 × 107, 2.0 × 107 3.7 × 108, 3.2 × 107
 2113 1.3 × 105, 4.1 × 105 6.7 × 108, 6.3 × 108 1.5 × 108, 1.0 × 107 4.4 × 108, 3.3 × 107
*Determined in duplicate. 
Figure 1. Frequency of rifampin (RIF)-resistant mutants in 
Mycobacterium tuberculosis Beijing and East-African/Indian (EAI) 
genotype strains (5 strains each) originating from Vietnam. Mutation 
frequencies were determined in duplicate. Statistical analysis was 
performed by using an unpaired Mann-Whitney test.
exposure to RIF concentrations of 2–32 mg/L selected 
resistant mutants only; this was not observed in EAI-1627 
cultures. Analysis of RIF-resistant Beijing mutants showed 
the following altered rpoB gene sequences: CAC→GAC 
(H526D), CAC→TAC (H526Y), and TCG→TTG 
(S531L), as assessed by using the GenoType MTBDRplus 
(Hain Lifescience, Nehren, Germany) assay (for details, 
see the online Technical Appendix).
For 3 of the 4 anti-TB drugs, the difference in the 
range of mutant prevention concentrations for the Beijing 
and EAI genotype strains was small: INH, 128–256 mg/L; 
RIF, 256–1,024 mg/L; and MXF, 2–8 mg/L. The mutant 
prevention concentration for AMK was >1,024 mg/L for 
all strains tested.
Conclusions
We showed that the currently used anti-TB drug 
susceptibility assays do not discriminate between the in 
vitro susceptibility, as determined by the methods used in 
this study, of the M. tuberculosis Beijing and EAI genotype 
strains. We also showed that the determination of mutation 
frequencies might be more informative than results of 
anti-TB drug susceptibility assays. For RIF, mutation 
frequencies in Beijing genotype strains were high compared 
with those in EAI genotype strains, and the selection of 
RIF-resistant mutants among Beijing strains, but not EAI 
strains, occurred within a wide range of RIF concentrations. 
In addition, the killing capacity of RIF toward the Beijing 
genotype is dependent on the density of mycobacteria: 
high concentrations of RIF are required to achieve 100% 
killing of high-density Beijing genotype populations but 
not of high-density EAI genotype populations. These in 
vitro characteristics might contribute to the less favorable 
treatment outcome of Beijing genotype TB infections 
and their signifi cant association with drug resistance. Our 
fi ndings demonstrate the need for anti-TB drug treatments 
that will prevent resistance among M. tuberculosis Beijing 
genotype TB cases, and they suggest that the development 
of genotype-specifi c TB therapy might be justifi ed.
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Figure 2. Concentration- and time-dependent bactericidal effect 
of rifampin (RIF) toward low-density cultures of Mycobacterium 
tuberculosis BE-1585 (5.1 × 105 CFU/mL) (A) and M. tuberculosis 
EAI-1627 (6.8 × 105 CFU/mL) (B). Cultures were exposed to RIF 
at 2-fold increasing concentrations for 6 days at 37°C. After 1, 
3, or 6 days of exposure, subcultures were performed on solid 
media to count CFUs. *Accurate CFU counting could not be 
performed because complete outgrowth of mycobacteria occurred 
on the sixth day of RIF exposure, leading to aggregation.
Table 2. Concentration- and time-dependent bactericidal effect of rifampin toward Mycobacterium tuberculosis genotypes in low- and 
high-density cultures* 
Day 
Lowest RIF concentration resulting in killing of M. tuberculosis, mg/L 
Beijing-1585 genotype EAI-1627 genotype 
>99% killing 100% killing >99% killing 100% killing 
Low† High‡ Low† High‡ Low§ High¶ Low§ High¶ 
1 8 ND  256 ND  8 ND  32 ND 
3 1 0.008  64 1024  0.125 0.03  8 32 
6 0.001 0.008  2 64  0.001 0.06  1 2 
*Cultures were exposed to RIF at 2-fold increasing concentrations for 6 days at 37°C; at indicated time-points, subcultures were performed on solid media 
for counting. Low, low-density culture; high, high-density culture; ND, not determined. 
†Density of 5.1 × 105 CFU/mL. 
‡Density of 4.4 × 106 CFU/mL. 
§Density of 6.8 × 105 CFU/mL. 
¶Density of 3.0 × 106 CFU/mL. 
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